3SOF

And away we go!!!!

cheers,
SJ

Hi sir_joke,

Do you have some news? What's happen with XKEM?

Anyone still following this?  Company is going to be at a Sickle Cell Conference in Dallas within the next few days.  Also possible news about a loan approval.  Stock has been steadily rising past few days decently and volume is starting to pick back up I think.  Also just crossed the 50dma.
If only I knew how to post a chart.  Anyways here is this, http://stockcharts.com/h-sc/ui?s=xkem

Up another 10% today.  Anyone care to give any advice on the technicals?

News:

Xechem Receives $473,181 SBIR Grant From NIH-NHLBI to Conduct Toxicity Studies of 5-HMF Compound
Wednesday October 4, 6:30 am ET

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that it has received a SBIR grant in the amount of $473,181 from the National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NHLBI) to carry out the toxicity studies on the five-membered heterocyclic anti-sickling compound known as 5-HMF. Researchers from both Virginia Commonwealth University (VCU) and Children's Hospital of Philadelphia (CHOP), University of Pennsylvania are expected to participate in the 5-HMF trials.

ADVERTISEMENT
As previously reported, Xechem acquired the exclusive worldwide rights for 5-HMF in December 2005 under a license agreement with VCU and on May 26th, 2006, Xechem was successful in obtaining Orphan Drug designation from the US Food and Drug Administration (FDA) for the drug. Research led by Dr. Donald Abraham of VCU has shown 5-HMF to be "the best potential anti-sickling agent in 30 years of sickle cell research," performed by his group. 5-HMF not only is a natural product with very little, if any, toxicity, but it has a high affinity for sickle cell hemoglobin. It is also very active in genetically modified mice as shown by Dr. Toshio Asakura, and his colleagues at the NIH-NHLBI Sickle Cell Disease Reference Laboratory at CHOP.

According to Xechem's Chairman and CEO, Dr. Ramesh Pandey, "We are very pleased to have received this significant grant to fund the toxicity studies of 5-HMF, which has shown great promise as a new type of anti-sickling agent that interacts specifically with intracellular hemoglobin without interacting with other proteins in the body. The grant award will allow us to immediately move forward on the 5-HMF front as we continue with our ongoing efforts to expand our production capability for our first sickle cell drug (NICOSAN(TM)), which was launched in Nigeria on July 6th, 2006."

5-HMF is a single compound which, subject to further testing and trials, could be effective for intravenous and/or oral use in the fight against Sickle Cell Disease. Previously, the Company acquired the exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Federal Government of Nigeria, for the research, development, manufacture, marketing and distribution of NICOSAN(TM)/HEMOXIN(TM), an all Natural Herbal Drug (phyto-pharmaceutical) that was launched in Nigeria on July 6th, 2006.

This stock will eventually make money.
Lalitha

production news and facility construction should be out by the end of this month.

All reports are positive so far out of Nigeria. Plenty of demand and government support for the program so some $$ is flowing.  full-scale facility finished by mid-summer 2007.

Currently building a position again... range $.022 to $.025, sell to build $.033 to $.037...

probably won't spike above that and remain until after substantial numbers reported.

cheers,
SJ

ps. Chassman has gotten most of her money back out which substantially improves xkem's finances.

Moving on news
Hey Terliso, is that the 3 magic lines going on here?

Wednesday, October 18 2006 12:46 PM, EST


U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria

Business Wire    "US Press Releases "

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--

Xechem International, Inc. (OTC BB: XKEM) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.

Funds Earmarked for Establishment of State-of-the-Art Pharmaceutical Facility in Sheda Science Village, Sheda, FCT, Abuja, Nigeria

The funds to be provided by UPS Capital under the Ex-Im guaranteed loan will be used to purchase the U.S. manufactured plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art pharmaceutical facility. The first phase of construction of the new facility began in July of this year. The total cost of the project is estimated at $12.45 million, of which $9.38 million will come from the U.S. loan. The expanded pharmaceutical facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem's breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).

Xechem Nigeria received regulatory approval for the manufacture, sales and marketing of NICOSAN(TM) from Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on July 3rd, 2006, and officially launched the drug just a few days later at a ceremony presided over by His Excellency, General Olusegun Obasanjo, the President of Nigeria. The drug is currently being produced by Xechem Nigeria in limited quantities at its pilot-scale facility in Abuja.

Dr. Ramesh Pandey, Chairman and CEO of the Xechem Companies said, "We are very pleased that this most anticipated guarantee from the U.S. Ex-Im Bank has now been approved and that we can now accelerate pursuit of our dream of building what we believe will be one of the finest state-of-the-art cGMP standard pharmaceutical facilities in Nigeria. Even more importantly, the Ex-Im guaranteed loan will help insure that we can produce commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease. We are very grateful to Ex-Im Bank, UPS Business Credit, Access Bank and Diamond Bank, as well as our financial consultants, Financialbridge, Inc., for their support for this important project and for helping us make the dream a reality."

About Sickle Cell Disease

Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its primary focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.

Am I prophetic, or what?

cheers,
SJ

ps.  the answer is  "what"   

Just some of my idle thoughts...
Are ordinary folk like me timid about posting on this board, or are there simply that few investors in XKEM?  I resent YHOO for not enabling message boards for any company that people desire to discuss, so I look to 3SOF for a more active discussion of XKEM - a company that seems to merit better coverage than it is presently receiving.
No opinions here about the proposed authorizing of 3BLN more shares?  What happened with that?  Is it one of the reasons that XKEM experiences brief spikes on positive news, and promptly retraces?  I've been following SSSU lately (since I found mention of it here a few months back), and have to say I'm somewhat perturbed by the steady upward track of the share price of some questionable entertainment-related enterprise while a company that has proven medical merit with incredible earnings prospects for the not-too-distant future struggles (and fails, so far) to keep pace.
This ExIm loan guarantee, IMO should lift XKEM's s/p to a new trading range - who are these weak hands selling under 3 cents?  I've been accumulating XKEM for nearly a year - most of it more recently, every time it dips below 2.4 cents (considering where it's headed today - I may have another opportunity <sigh>).  I'm not interested in selling any shares for at least the next year, possibly two - once the company is in a full manufacturing and distribution phase.  Will XKEM have the dubious distinction of issuing an ER with exponential profit only to have it's stock price retrace to 2.7 cents the next day?  Is XKEM stock destined to remain the province of (fractional) penny flippers? 
Sorry if my cynicism is all too apparent, maybe it's the reason I post infrequently.  I'm hesitating to post this, but I think I need to share some of my thoughts with the rest of you just to get some perspective, so thanks for reading.  Perhaps I should change my handle to:
Eeyore.

your bitterness and resignation go hand in hand with XKEM. I must say that it has been a long and frustrating road with this company. I've been involved with it for many years on a financial and scientific basis, and I must confess that your frustration mirrors mine. Loans have been made and wasted. Money has come and gone. Shares have been issued and issued and issued.. which is why it languishes here in penny land.  Medically, this company has and will serve an important purpose in the lives of those suffering from SCD, but that is a low market here in the US and thus of very little consequence to the investment world.  One just has to go back to the days of taxol and BMS preventing other sources from taking away business from its chemotherapy market.  Plenty of ways to get/purify/make paclitaxel but all were either bought, destroyed or courted out of business.  In the long run,this compnay will survive but it won't make anyone wealthy except for the crooks.

My advice, is build a position slowly... sell those shares that you acquire below 2.4 cents at anything above 3.5 for the next 9 to 12 months... This is where the trading range will remain.

eventually you will own a completely "free" position, and it won't hurt so much worrying aobut the damn company.

cheers,
SJ

Anyone care to give me an opinion on the current chart?  Possibly reversing the downtrend?

Anyone?

.

Damnit, how do I add charts?

Heres the link anyhow. 
http://stockcharts.com/h-sc/ui?s=xkem

This site just doesn't seem to be what it used to.   

Looks to me as this has made a BreakOut
From a Triple Bottom (reversal) Pattern.
Last 5 trading days has made a Strong move to bust the 50-day and
the 200-day MA's.
Don't chase it, at this point in time I would watch and wait for a pullback and
buy the dip. Let the 50-day MA catch up.

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
46.62%above 13-day MA
57.57%above 50-day MA


Triple Bottom (Reversal)

The triple bottom is a reversal pattern made up of three equal lows followed by a breakout above resistance. While this pattern can form over just a few months, it is usually a long-term pattern that covers many months. Because of its long-term nature, weekly charts can be best suited for analysis.

As the triple bottom develops, it can start to resemble a number of patterns. Before the third low forms, the pattern may look like a double bottom. Three equal lows can also be found in a descending triangle or rectangle. Of these patterns mentioned, only the descending triangle has bearish overtones; the others are neutral until a breakout occurs. Similarly, the triple bottom should also be treated as a neutral pattern until a breakout occurs. The ability to hold support is bullish, but demand has not won the battle until resistance is broken. Volume on the last advance can sometimes yield a clue. If there is a sharp increase in volume and momentum, then the chances of a breakout increase.

Quote from: sir_joke on October 25, 2006, 12:20:13 PM
your bitterness and resignation go hand in hand with XKEM. I must say that it has been a long and frustrating road with this company. I've been involved with it for many years on a financial and scientific basis, and I must confess that your frustration mirrors mine. Loans have been made and wasted. Money has come and gone. Shares have been issued and issued and issued.. which is why it languishes here in penny land.  Medically, this company has and will serve an important purpose in the lives of those suffering from SCD, but that is a low market here in the US and thus of very little consequence to the investment world.  One just has to go back to the days of taxol and BMS preventing other sources from taking away business from its chemotherapy market.  Plenty of ways to get/purify/make paclitaxel but all were either bought, destroyed or courted out of business.  In the long run,this compnay will survive but it won't make anyone wealthy except for the crooks.

My advice, is build a position slowly... sell those shares that you acquire below 2.4 cents at anything above 3.5 for the next 9 to 12 months... This is where the trading range will remain.

eventually you will own a completely "free" position, and it won't hurt so much worrying aobut the damn company.

cheers,
SJ

this still holds true....

cheers,

SJ

watch for the breakdown to below $.02 again.